Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors, many of which are beyond the Company's control, including but not limited to risks related to research and development activities, scientific and technical challenges, formulation and manufacturing difficulties, clinical study preparation and execution, bioanalytical testing, pharmacokinetic outcomes, safety and tolerability findings, the possibility that preclinical or early-stage results may not be predictive of future clinical results, uncertainties relating to regulatory review and approval processes, intellectual property protection and enforcement risks, reliance on third-party advisors, contract research organizations, manufacturers, development partners and suppliers, competitive technologies, market acceptance, financing availability, and general economic, financial, regulatory, and capital market conditions
& Unwin, R
GLP-1 receptor agonist (GLP-1 RAs) are mostly approved for T2DM in China till 2023, including but not limited to Liraglutide, Semaglutide and Dulaglutide
Each vial of KLOW contains a specific ratio of high-purity peptides for experimental signaling models
Understanding what is changing requires moving beyond the drug itself and examining how its meaning shifts depending on why it is prescribed
ggvenn: Draw Venn Diagram by ggplot2